Photo credit: East Point Hospital
By Victor Akhidenor
For nearly four months, 34-year-old tailor Odion Osin convinced himself that his persistent, dry cough was merely the physical price of his trade. A consequence of inhaling textile dust and diesel fumes in his cramped workshop in the Ujoelen area of Ekpoma, Edo State.
By the time severe night sweats, chest pain, and a 15-kilogram weight loss forced him to seek medical attention at a tertiary chest clinic, the diagnosis was far more complex than standard tuberculosis. Osin was diagnosed with Drug-Resistant Tuberculosis (DR-TB). A severe strain of the bacterium Mycobacterium tuberculosis that does not respond to standard first-line antibiotic treatments.
“The word ‘resistant’ sounded to me like an absolute death sentence,” Osin recalls, sitting in the shade outside his home.
“But the medical diagnosis was only half the trauma. The moment word got out in the neighbourhood, customers stopped bringing fabrics to my shop. People would walk past my house and hold their clothes over their faces. The isolation and shame were far harder to endure than the daily nausea or the weakness.”
Osin’s trial highlights a lingering paradox in Nigeria’s public health landscape: while medical science has dramatically improved the clinical prognosis for DR-TB, public understanding remains trapped in decades-old misconceptions.
The Clinical Progress vs. The Social Reality
Historically, treating drug-resistant strains required two years of agonising therapy, involving daily painful injections and cocktail regimens with severe side effects, including hearing loss and psychosis. Today, the clinical reality is far more hopeful. The introduction of shorter, all-oral regimens, such as the BPaLM combination (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin), has reduced treatment timelines to 6 to 9 months, eliminated injections, and significantly improved cure rates.
Yet, despite free diagnostic testing and medication provided through government facilities and international funding partners, case finding and treatment completion rates still lag. Medical experts point directly to social stigma as the primary driver keeping symptomatic individuals in the dark.
“Stigma acts as a formidable barrier at every stage of the care cascade,” explains Dr Andrew Eigbedion, the CMD of Oseohe Medical Centre based in Ekpoma.
“It prevents people from getting screened when symptoms first appear, leads them to hide their status from household members, and causes many to abandon their medication midway once they experience social rejection.”
Grassroots Interventions: The Power of Peer Adherence Supporters
To bridge the dangerous gap between clinical availability and community acceptance, non-governmental organisations and state health boards have increasingly turned to a specialised frontline workforce: Treatment Adherence Supporters (TAS), many of whom are DR-TB survivors themselves.
Every morning, these community workers navigate the narrow, unpaved alleyways of dense urban settlements to conduct home visits. They ensure patients take their daily medication, monitor for adverse drug reactions, and provide household education on basic infection control—such as proper ventilation and cough hygiene.
“You cannot separate the medical treatment from the social environment,” says Jane Oaiya, a community health advocate who completed her own DR-TB treatment in 2023 and now manages a network of 12 peer supporters in Edo State.
“When we visit a home, we aren’t just handing over pills. We talk to the spouse, the landlord, and the neighbours. We explain that once a patient is on appropriate treatment for a few weeks, their infectiousness drops dramatically. Education is what turns fear into support.”
Reclaiming Lives Beyond the Clinic
For Osin, the intervention of a local peer supporter was the turning point. Beyond monitoring his medication schedule, his supporter engaged directly with his family and local trade association, dispelling myths about how the disease spreads.
After nine months of strict adherence to his all-oral regimen, Osin received a clean bill of health early this year. Today, he has reopened his tailoring shop and serves as a volunteer community educator, using his own story to encourage others with persistent coughs to step forward for free testing.
“When people see me back at my sewing machine, healthy and strong, the fear evaporates far faster than any lecture could achieve,” Osin says.
“The medicine cured my lungs, but community support is what restored my life.”